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OBJECTIVE—Islet -cells loose their ability to synthesize insu-
lin under diabetic conditions, which is at least partially due to the
decreased activity of insulin transcription factors such as MafA.
Although an in vitro study showed that reactive oxygen species
(ROS) decrease MafA expression, the underlying mechanism still
remains unclear. In this study, we examined the effects of c-Jun,
which is known to be upregulated by ROS, on the expression of
MafA under diabetic conditions.
RESEARCH DESIGN AND METHODS—To examine the pro-
tein levels of MafA and c-Jun, we performed histological analysis
and Western blotting using diabetic db/db mice. In addition, to
evaluate the possible effects of c-Jun on MafA expression, we
performed adenoviral overexpression of c-Jun in the MIN6 -cell
line and freshly isolated islets.
RESULTS—MafA expression was markedly decreased in the
islets of db/db mice, while in contrast c-Jun expression was
increased. Costaining of these factors in the islets of db/db mice
clearly showed that MafA and insulin levels are decreased in
c-Jun–positive cells. Consistent with these results, overexpres-
sion of c-Jun signiﬁcantly decreased MafA expression, accompa-
nied by suppression of insulin expression. Importantly, MafA
overexpression restored the insulin promoter activity and pro-
tein levels that were suppressed by c-Jun. These results indicate
that the decreased insulin biosynthesis induced by c-Jun is
principally mediated by the suppression of MafA activity.
CONCLUSIONS—It is likely that the augmented expression of
c-Jun in diabetic islets decreases MafA expression and thereby
reduces insulin biosynthesis, which is often observed in type 2
diabetes. Diabetes 59:1709–1720, 2010
T
he development of type 2 diabetes is associated
with islet -cell dysfunction and insulin resis-
tance. Normal -cells can compensate for insulin
resistance by increasing insulin secretion and/or
-cell mass (1), but insufﬁcient compensation leads to the
onset of glucose intolerance. Once hyperglycemia be-
comes apparent, -cell function, including insulin biosyn-
thesis, progressively deteriorates. This process is often
observed in type 2 diabetic patients and is well known as
-cell glucose toxicity.
Insulin biosynthesis is principally regulated by key
insulin transcription factors including pancreatic and du-
odenal homeobox (PDX)-1 (formerly known as IPF-1,
STF-1, and IDX-1) (2–4), BETA2 (5), and MafA (6–8). It
was previously reported that chronic hyperglycemia sup-
presses insulin gene expression due to the decreased
binding of PDX-1 and RIPE3b1 activator/MafA to its pro-
moter region (9–12). It has been suggested that reactive
oxygen species (ROS) are involved in the suppression of
insulin biosynthesis, which is often observed in type 2
diabetes.
Islet -cells are thought to be vulnerable to oxidative
stress, since expression levels of antioxidant enzymes
such as catalase and glutathione peroxidase are very low
in -cells compared with other tissues (13,14). In fact,
it has been demonstrated that oxidative stress markers
such as 8-hydroxy-2-deoxyguanosine, 4-hydroxy-2-non-
enal (HNE)-modiﬁed proteins and heme oxygenase-1 are
increased in islet -cells of diabetic rats and mice (15,16).
Some groups, including ourselves, previously showed that
antioxidants restore the suppressed binding activity and
expression of PDX-1 in the islets of different diabetic
model animals (17,18). It was also reported that MafA
protein levels are suppressed at the posttranslational level
under chronic high-glucose conditions in cell line–based
experiments and that antioxidant treatment restores the
suppression of MafA by high glucose (18,19). However, it
remains unclear as to whether MafA expression is de-
creased under diabetic conditions in vivo and, if so, what
factor(s) mediate the suppression of MafA by oxidative
stress.
It is well known that ROS activate several kinases, such
as p38 mitogen–activated protein kinase (p38) and c-Jun
NH2-terminal kinase (JNK), in several tissues including
pancreatic islets (20–22). The amount and activity of
c-Jun, which is phosphorylated by JNK, are also increased
by ROS (23,24). Importantly, expression and activity of
c-Jun are upregulated by high glucose and glycation prod-
ucts in several tissues (25,26). However, it was still unclear
as to whether c-Jun is actually upregulated in islets under
diabetic conditions. So far, several reports have indicated
the effects of these ROS-activated factors on insulin tran-
scription factors; for example, p38 acts as a kinase acti-
vating MafA (27) and JNK activation translocates PDX-1
from the nucleus to the cytoplasm (28). In particular, two
reports (29,30) clearly demonstarted that c-Jun dramati-
cally suppressed the insulin promoter activity. These in
vitro studies showed that c-Jun inhibits transcriptional
activity of the human and mouse insulin gene through the
cAMP response element (CRE) and RIPE3 element located
in the insulin enhancer region. Interestingly, we previously
reported that MafA binds not only RIPE3b1 but also to
other Maf response elements (MAREs) including CRE
(31). From these ﬁndings we speculated that c-Jun is a
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tern of c-Jun in islets under diabetic conditions has not
been clearly reported.
In this study, we analyzed the c-Jun and MafA expres-
sion pattern and levels in db/db mice, a model of type 2
diabetes, and MafA protein expression was found to be
low or almost undetectable in c-Jun–positive cells. Fur-
thermore, we show that MafA expression is suppressed
upon c-Jun overexpression in islet -cells, coinciding with
the reduction of insulin gene transcription. Signiﬁcantly,
MafA overexpression or c-Jun knockdown restored the
insulin gene expression in diabetic islets.
RESEARCH DESIGN AND METHODS
Preparation of expression plasmids and reporter gene analysis. The
238 insulin ﬁreﬂy luciferase (238 Insulin luc) expression plasmid contain
rat insulin 2 gene sequences from 238 to 2 bp (32). The cytomegalovirus
(CMV) enhancer-driven rat c-Jun, human JNK, p38 (CSBP2), and mouse
MafA expression vectors were constructed by subcloning coding sequences
into the pAdTrack-CMV or pcDNA3.1 expression vector. Myc-tagged MafA
was produced by subcloning mouse MafA coding sequences into pcDNA6/
myc-His (Invitrogen). 238 insulin LUC (0.25 g) was transfected into cells
with the control empty vector, pAdTrack, and/or the indicated expression
vectors (1.0 g in total) using LIPOFECTAmine (Invitrogen), together with the
thymidine kinase promoter-driven renilla luciferase expression plasmid (20 ng
phRL-TK; Promega Madison, WI) serving as an internal control.
Preparation of adenoviruses. Recombinant adenoviruses expressing c-Jun,
JNK, p38, and MafA were prepared using the AdEasy system as described
previously (33). An adenovirus expressing a small-interfering RNA against
mouse c-Jun (Ad-si-cJun) was constructed using the following oligonucleo-
tides as described previously (34): 5-CGCGTAAGCTGATTACTGTCAATA
AATTCAAGAGATTTATTGACAGTAATCAGCTTTTTTTTGGAAA-3 and 5-
AGCTTTTCCAAAAAAAAGCTGATTACTGTCAATAAATCTCTTGAATTTATTG
ACAGTAATCAGCTTA-3 (c-Jun sequences are underlined). These oligonucle-
otides were annealed and inserted into the MluI/HindIII sites of the pRNAT-
H1.1/Adeno shuttle plasmid (GenScript, Piscataway, NJ). Adenovirus titer was
roughly 10
10 plaque-forming units (pfu)/ml after puriﬁcation with the Adeno-X
Virus Puriﬁcation kit (Clontech), as estimated using the Adeno-X Titer kit
(Clontech).
Isolation of mouse pancreatic islets. To isolate mouse islets, 1.5 mg/ml
of collagenase plus protease inhibitor (Sigma-Aldrich) and hyaluronidase
(Sigma-Aldrich) were injected into the pancreatic duct. The isolated pancreas
was digested in a 37°C incubator for 20 min. After washing and precipitating
with 0.25 mol/l sucrose, islets were hand picked.
Real-time PCR analysis. Real-time PCR analysis was performed as de-
scribed previously (34). Primer sets for mouse insulin 1 (numbering relative to
ATG, forward 47 GACCAGCTATAATCAGAGACC, reverse 331 AGTTG
CAGTAGTTCTCCAGCTG, 378 bp product), mouse insulin 2 (forward 57
AGCCCTAAGTGATCCGCTACAA, reverse 331 AGTTGCAGTAGTTCTC
CAGCTG, 388 bp), mouse MafA (forward 757 TTCAGCAAGGAGGAGGT
CAT, reverse 973 CCGCCAACTTCTCGTATTTC, 217 bp), mouse PDX-1
(forward 192 CATCTCCCCATACGAAGTGC, reverse 526 GGGGCCGG
GAGATGTATTTG, 335 bp), mouse c-Jun (forward 736 TCCCCTATCGACAT
GGAGTC, reverse 881 TTTTGCGCTTTCAAGGTTTT, 146 bp), and mouse
-actin (forward 778 GCTCTTTTCCAGCCTTCCTT, reverse 945 CTTCTG
CATCCTGTCAGCAA, 168 bp) were utilized to detect speciﬁc bands for each
factor.
Northern blotting. Total RNA or Poly(A)
mRNA was separated under
denaturing conditions on 1% agarose gels. The transferred RNA was hybrid-
ized with a
32P-labeled mouse MafA (314–490 bp; numbering relative to ATG),
mouse insulin (35), mouse PDX-1 (622–852 bp), or mouse- actin (53–549 bp)
cDNA probe.
Western blot analysis. MIN6 nuclear extracts were prepared as described
previously (34) at the indicated times or 60 h after the adenovirus infection.
Islet nuclear extracts were prepared with a nuclear extraction kit (Active
Motif, Carlsbad, CA). Western blot analysis was performed as described
previously (34), with the following antibodies and dilutions: rabbit anti-MafA
antibody (8), 1:1,000; rabbit anti–c-Jun antibody (no. 9165; Cell Signaling
Technology, Danvers, MA), 1:200; rabbit anti–PDX-1 antibody (17), 1:2,000;
and goat anti-actin antibody (no. sc-1615; Santa Cruz Biotechnology), 1:2,000.
Enzyme-linked immunosorbent assay for insulin. Whole-cell extracts
were obtained from 100 islets from each group of mice or adenovirus-
infected MIN6 cells by treating for 24 h at 4°C in acid-ethanol. The insulin
content of the extract was determined with the Mouse Insulin ELISA kit
(Morinaga Biochemicals, Yokohama, Japan). Insulin concentration was nor-
malized with total cellular protein, as measured using the Bio-Rad protein
assay kit (Bio Rad Laboratories, Richmond, CA).
Immunohistochemistry. Pancreata were dissected and ﬁxed overnight in 4%
paraformaldehyde. Fixed tissues were processed routinely for parafﬁn embed-
ding and sectioned. After treatment with 1% blocking goat or donkey serum,
sections were immunostained for MafA, c-Jun, and insulin with the following
antibodies and dilutions: rabbit (8) and our newly produced goat antibodies
against MafA, 1:1,000 and 1:200, respectively; rabbit anti–c-Jun (no. 9165; Cell
Signaling Technology), 1:200; guinea pig anti-insulin (no. A0564; DAKO,
Glostrup, Denmark), 1:2000; guinea pig anti-glucagon (Linco, St. Charles, MO),
1:500; sheep anti-somatostatin (American Research Products, Belmont, MA),
1:500; and guinea pig anti–pancreatic polypeptide antibodies (Linco), 1:500.
For the single detection of MafA or c-Jun, a Vectastain Elite ABC kit (Vector
Laboratories) was utilized. For the combined staining of c-Jun, MafA, and
insulin, we used Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 555
donkey anti-goat IgG (Molecular Probes, Eugene, OR), and donkey Cy5-
conjugated anti–guinea pig IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA), respectively, at a dilution of 1:200. For the costaining of
glucagon, somatostatin, and pancreatic polypeptide, we used donkey Cy5-
conjugated anti–guinea pig IgG and donkey Cy5-conjugated anti-sheep IgG as
secondary antibodies at a dilution of 1:200. Fluorescent images were captured
using a BIO-RAD Radience 2100 confocal microscope.
Immunocytochemistry. Sixty hours after the infection of adenoviruses or
the transfection of expression plasmids, MIN6 cells were ﬁxed on Lab-Tek
chamber slides, and mouse islets were ﬁxed on a poly-D-lysine cell culture
plate with 4% paraformaldehyde. After the treatment with 0.1% Triton X-100
for the induction of cell permeability, the slides were incubated with 1%
blocking goat serum. To detect MafA, MafA-myc fusion protein, c-Jun, and
insulin, we performed immunocytochemistry with rabbit anti-MafA at 1:1,000
dilution (8), mouse anti–c-myc at 1:200 dilution (no. sc-40; Santa Cruz
Biotechnology), rabbit anti–c-Jun at 1:200 dilution (no. 9165; Cell Signaling
Technology), and guinea pig anti-insulin antibodies at 1:2,000 dilution (no.
A0564; DAKO). Cells were then exposed to the secondary antibodies (Alexa
Fluor 596 goat anti-rabbit IgG for MafA and Alexa Fluor 596 goat anti–guinea
pig IgG for insulin at 1:200 dilution), and images were captured using a Nikon
microscope digital camera (DXM1200F). Other secondary antibodies were
used for detection with the Bio-Rad Radience 2100 confocal microscope
(Alexa Fluor 546 goat anti-mouse IgG for myc, Alexa Fluor 488 donkey
anti-rabbit IgG (Molecular Probes) for c-Jun, and donkey Cy5-conjugated
anti–guinea pig IgG (Jackson ImmunoResearch Laboratories) for insulin at
1:200 dilution.
Statistical analysis. Data are expressed as means  SD. Statistical analysis
was performed using one-way ANOVA followed by the Scheffe test. A value of
P 	 0.05 was considered to be statistically signiﬁcant.
RESULTS
Marked decrease of MafA expression under diabetic
conditions. C57 BLKsJ db/db (db/db) mice have been
established as a type 2 diabetic model with obesity. In
db/db mice, hyperinsulinemia is observed to compensate
for the increased insulin resistance. However, after 
12
weeks of age, plasma insulin levels begin to decrease, as
shown in Fig. 1A. This alteration of insulin levels is similar
to that observed in type 2 diabetic patients. To evaluate
whether the key insulin transcription factor MafA is also
affected under diabetic conditions in vivo, we performed
immunohistochemistry with an anti-MafA antibody (Fig.
1A). In db/db mice, MafA expression in pancreatic islet
nuclei was markedly decreased after 12 weeks of age and
was not clearly detected at 17 and 22 weeks of age,
whereas control m/m mice retained MafA expression at
least up to 22 weeks old. These ﬁndings were consistent
with the proﬁle of plasma insulin and blood glucose levels.
Increased expression of c-Jun in pancreatic islets
under diabetic conditions. Since c-Jun activity and
protein levels are increased in response to oxidative stress
(23,24), which leads to suppression of insulin promoter
activity in vitro, we evaluated in this study whether c-Jun
expression is upregulated in the islets of diabetic mice that
are exposed to oxidative stress. As shown in Fig. 1B, c-Jun
expression was clearly detected in duct cells and a small
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age and diabetic db/db mice at 7 weeks of age. However,
the number of c-Jun–positive cells gradually increased
with age in the islets of db/db mice. At 12 weeks of age,
several c-Jun–positive islet cells were detected, and at 17
and 22 weeks of age a larger number of c-Jun–positive
cells were detected. Interestingly, this expression pattern
of c-Jun paralleled the loss of MafA expression (Fig. 1A).
Quantitative real-time PCR analysis, using freshly isolated
islets from m/m and db/db mice at 17 weeks of age, clearly
demonstrated that both MafA and insulin mRNA levels
were markedly decreased (Fig. 1C). In contrast, c-Jun
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FIG. 1. Altered expression levels of MafA and c-Jun in diabetic islets. A: Pancreatic sections from 7-, 12-, 17-, and 22-week-old normal control m/m
(upper panels) and diabetic db/db (lower panels) mice were immunostained with a MafA antibody. Fasting insulin and glucose levels in m/m and
db/db mice at 7, 12, 17, and 22 weeks of age are indicated under each panel (n  3). B: Pancreatic sections from 7-, 12-, 17-, and 22-week-old m/m
(upper panels) and db/db (lower panels) mice were immunostained with a c-Jun antibody. C: Total RNA of freshly isolated islets from m/m and
db/db mice at 17 weeks of age was utilized for real-time PCR analysis. mRNA levels of insulin 1, insulin 2, MafA, and c-Jun were quantiﬁed and
normalized with that of -actin. Each mRNA level of db/db mice was presented as the relative amount  SD with that of m/m being arbitrarily
set at 100 (n  3). *P < 0.05; **P < 0.001 vs. each mRNA level of m/m mice.
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was consistent with the expression pattern of MafA and
c-Jun observed by immunohistochemistry.
MafA and insulin expression is reduced in islet c-
Jun–positive cells. Our results implied that the increased
level of c-Jun caused a decrease in MafA and insulin gene
m/m 
db/db 
7 w  17 w  A 
Insulin 
c-Jun 
MafA 
21 w  7 w 
Insulin 
c-Jun 
MafA 
KK-Ay 
C57BL/6  
B 
17 w db/db  C 
E
glucagon,  
somatostatin,  
pancreatic polypeptide 
c-Jun 
MafA  
7w m/m
7w BL6
21w BL6
7w KKAy
21w KKAy
7w db/db
17w db/db
17w m/m
PDX1 
actin 
c-Jun 
D 
0 
30 
10 
20 
0 
30 
10 
20 
** 
** 
*  ** 
*  ** 
I
s
l
e
t
 
i
n
s
u
l
i
n
 
c
o
n
t
e
n
t
 
(
m
g
/
g
 
p
r
o
t
)
 
7w m/m
7w BL6
21w BL6
7w KKAy
21w KKAy
7w db/db
17w db/db
17w m/m
FIG. 2. Suppression of MafA and insulin expression in c-Jun-positive cells. A: Pancreatic sections from 7- and 17-week-old m/m (upper panel) and
db/db (lower panel) mice were costained with anti-MafA (red), c-Jun (green), and insulin (blue) antibodies. B: Pancreatic islets of another
diabetic model, KK-Ay mice, and C57BL6 mice as normal control at 7 and 21 weeks of age were costained as described in A. C: A pancreatic islet
(circled by the dotted line) of a 17-week-old db/db mouse was costained with antibodies against c-Jun (red) and non–-cell hormones (blue)
including glucagon, somatostain, and PP. D: Five micrograms of islet nuclear protein from each group of db/db and m/m mice and 10 g of islet
nuclear protein from each group of KK-Ay and C57BL6 mice were applied for Western blotting analysis and probed with indicated antibodies. E:
Insulin content in the islets from each group of mice was measured with the mouse insulin ELISA kit (Morinaga Biochemicals, Yokohama, Japan).
Insulin concentration was normalized with total cellular protein. The normalized values  SD were calculated from four independent
experiments. *P < 0.05; **P < 0.001 vs. 17-week db/db or 21-week KKAy.
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FIG. 3. Marked suppression of MafA by c-Jun overexpression. A: The rat insulin 2 (238 to 2 bp)-driven ﬁreﬂy luciferase expression plasmid
(238 insulin luc) was cotransfected with c-Jun, JNK, p38/pAdTrack, or empty-vector pAdTrack into MIN6 cells. The ﬁreﬂy luciferase activity
from 238 insulin luc was normalized with the cotransfected phRL-TK renilla luciferase signal. The relative 238 insulin luc activity was
calculated as the ratio of luc activity after c-Jun, JNK, or p38/pAdTrack transfection to that after control pAdTrack transfection. Experiments
were performed at least four times, and the relative values are expressed as means  SD. *P < 0.001 vs. control pAd-Track. B: MIN6 cells were
infected with each indicated adenovirus. Sixty hours after the infection, nuclear protein was isolated and Western blotting (left panel) and
gel-shift (right panel) analysis were performed using 10 g of nuclear protein to detect MafA and PDX-1. C: Isolated mouse islets were infected
with Ad-c-Jun or control Ad-GFP. Sixty hours after the infection, nuclear protein was isolated and Western immunoblot analysis was performed
using 2 g of nuclear protein. Each factor was probed with indicated antibodies on the same blotting. D and E: Sixty hours after infection of the
indicated adenovirus to MIN6 (D) or cultured mouse islets (E), total RNA was isolated followed by real-time RT-PCR analysis to quantify the
mRNA levels of MafA, PDX-1, insulin 1, insulin 2, and control -actin. Each mRNA level was normalized with that of -actin and is presented as
relative amount  SD, with the ratio of each control mRNA level without adenovirus treatment (C) or Ad-GFP infection (D) being arbitrarily set
at 100 (n  4). *P < 0.01; **P < 0.001vs. each control mRNA.
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association in further detail, we ﬁrst performed immuno-
histochemistry with MafA, c-Jun, and insulin antibodies
using 7- and 17-week-old diabetic mice (Fig. 2A), as MafA
expression levels were markedly decreased between 7 and
17 weeks of age (Fig. 1A). Normal mice expressed a large
amount of insulin and MafA without enhanced c-Jun
expression as expected. In contrast, in db/db mice, insulin
expression was decreased in some cells in which MafA
was undetectable or weakly expressed compared with
control m/m mice. Interestingly, MafA and insulin expres-
sion was suppressed in most c-Jun–positive cells, which
became clearer in 17-week-old db/db mice. KK-Ay mice, in
which the Ay mutation is introduced onto a KK strain, are
also known as an obese diabetic model. Since KK-Ay mice
get severe diabetes after 
20 weeks, we used older mice
than db/db mice. In the KK-Ay islets, the number of
c-Jun–positive cells was increased with marked hypergly-
cemia (
200–300 mg/dl fasting glucose) at 21 weeks of
age, and both MafA and insulin protein levels were de-
creased in those cells, as observed in db/db mice (Fig. 2B).
To examine the distribution of c-Jun in islet cells, immu-
nohistochemistry was performed with antibodies against
c-Jun and non–-cell islet hormones, including glucagon,
somatostatin, and pancreatic polypeptide (PP). In the
islets of 17-week-old db/db mice, many c-Jun–positive cells
were observed without costaining of non–-cell hormones
(Fig. 2C), indicating that c-Jun was expressed in islet
-cells. To quantify the protein levels of MafA, c-Jun, and
insulin in the islets of normal and diabetic mice, Western
blotting using islet nuclear extracts and enzyme-linked
immunosorbent assay (ELISA) for islet insulin were per-
formed (Fig. 2D and E). c-Jun protein level was clearly
increased in the islets of 17-week-old db/db mice and of
21-week-old KK-Ay mice. In contrast, MafA protein level
was decreased in those islets. Consistent with the sup-
pressed expression of MafA, insulin content in the islets of
17-week-old db/db mice and 21-week-old KK-Ay mice were
signiﬁcantly decreased compared with control mice.
These ﬁndings suggest that c-Jun is involved in the sup-
pression of MafA and insulin expression under diabetic
conditions.
c-Jun overexpression markedly suppresses both
MafA and insulin expression. To evaluate the effects of
c-Jun on insulin gene transcription, we examined the
effects of c-Jun on insulin promoter activity in the MIN6
-cell line by reporter gene analysis. As shown in Fig. 3A,
c-Jun overexpression markedly decreased insulin pro-
moter activity to 30% of that observed in control, which
was consistent with previous reports (29,30). In addition,
although it is known that several kinases such as JNK and
p38 are activated by ROS in islet -cells in vivo (15,16),
their overexpression did not show signiﬁcant effects.
To further examine the impact of c-Jun on MafA in islet
-cells, we generated an adenovirus expressing both c-Jun
and green ﬂuorescent protein (GFP) (Ad-c-Jun). We ﬁrst
performed Western blotting using nuclear extract of MIN6
and islet cells and found that c-Jun protein expression was
almost undetectable in uninfected cells (data not shown).
As shown in Fig. 3B, adenoviral c-Jun overexpression
markedly suppressed MafA protein level and its DNA-
binding activity 60 h after the infection in MIN6 cells. The
protein level and DNA-binding activity of PDX-1 were not
apparently altered under these conditions. Northern blot-
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FIG. 4. Suppression of MafA and insulin protein expression by c-Jun overexpression. A: Immunostaining of MafA in red (upper panels) and
insulin in red (lower panels) was performed with MIN6 cells, 60 h after infection of Ad-c-Jun, which expresses c-Jun and GFP simultaneously.
B: Sixty hours after Ad-c-Jun (upper and middle panels) or Ad-GFP (lower panel) infection, normal mouse islets were immunostained with
anti-MafA and insulin antibodies, and captured with confocal microscopy. MafA is shown in red, insulin is shown in blue and Ad-c-Jun–infected
cells are shown in green by the GFP signal. Upper and middle panels showed the same islet but different sections. C: Insulin content of
Ad-c-Jun–infected islets was measured with ELISA. After normalized with protein concentration, insulin protein level was presented as relative
amount  SD, with the ratio of Ad-GFP treatment being arbitrarily set at 100 (n  4). *P < 0.05 vs. Ad-GFP infection.
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overexpression signiﬁcantly suppressed MafA mRNA level
(supplemental Fig. 1, available in the online appendix
at http://diabetes.diabetesjournals.org/cgi/content/full/
db08-0693/DC1/) (Fig. 3D). Adenoviral overexpression of
c-Jun in isolated mouse islets also markedly suppressed
MafA mRNA and protein levels (Fig. 3C and E). Consistent
with these results, the mRNA levels of insulin 1 and 2 were
suppressed by c-Jun overexpression in both MIN6 cells
and islets. A much smaller defect on PDX-1 mRNA was
also observed under these circumstances.
To directly observe and visualize the effect of c-Jun, we
performed immunocytochemistry using MIN6 and islet
cells. Adding only a low level of Ad-c-Jun (1.0 lo f1 10
9
pfu/ml to 1 ml of culture medium) enabled us to compare
MafA and insulin expression in c-Jun–expressing and
nonexpressing cells. In c-Jun–positive MIN6 cells, both
MafA and insulin expression were reduced (Fig. 4A), while
the negative control Ad-GFP had no effect (supplemental
Fig. 2). We also evaluated whether MafA and insulin were
affected by c-Jun overexpression in islets isolated from the
m/m mouse. As observed in MIN6 cells, protein levels of
MafA were markedly reduced in most Ad-c-Jun–infected
islet cells, while control Ad-GFP showed no effects on
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protein to evaluate the amount of mRNA and protein levels of MafA and control -actin. C: mRNA levels of MafA were quantiﬁed by real-time
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mRNA level without adenovirus treatment being arbitrarily set at 100 (n  4). D: Protein levels of MafA were quantiﬁed by densitometry. Each
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on insulin content in isolated islets, a large amount of
Ad-c-Jun (1.0 lo f1 10
10 pfu/ml to 1 ml of culture
medium) was used to overexpress c-Jun in entire islet
cells. Consistent with the results of immunocytochemistry,
insulin content measured by ELISA was signiﬁcantly de-
creased in c-Jun–overexpressed islets (Fig. 4C). These
ﬁndings directly demonstrate that c-Jun suppresses the
expression of both MafA and insulin.
c-Jun suppresses MafA expression at both transcrip-
tional and posttranslational levels. It was previously
reported that MafA protein level was suppressed at the
posttranslational level under chronic high-glucose condi-
tions in vitro (19). To examine how c-Jun suppresses
expression of MafA, protein and mRNA levels of MafA
were compared at different times after exposure to Ad-c-
Jun in MIN6 cells (Fig. 5A and B). Quantiﬁcation of mRNA
and protein levels showed that MafA protein levels are
markedly decreased with relatively small suppression of
mRNA levels within the ﬁrst 48 h after exposure (Fig. 5C
and D). To further evaluate the possibility of posttransla-
tional suppression of MafA, 24 h after Ad-c-Jun or Ad-GFP
infection, MIN6 cells were incubated with 10 g/ml of
cycloheximide (CHX) for another 24 h. As Fig. 5E shows,
protein level of MafA was markedly decreased by the 24-h
exposure to CHX with overexpression of control GFP
(lane 5). In the same condition, the loss of MafA was more
intensiﬁed with overexpression of c-Jun (lane 6), although
c-Jun had no effect on protein level of MafA within ﬁrst
2 4h( lane 2). These results suggest that c-Jun possibly
reduces MafA levels via a posttranslational mechanism,
although it was also observed that c-Jun signiﬁcantly
suppressed MafA at the mRNA level.
MafA restores the c-Jun–induced suppression of in-
sulin gene transcription and its protein level. Since
c-Jun decreased the expression of both MafA and insulin,
we speculated that c-Jun decreases insulin gene transcrip-
tion at least partially by mediating the suppression of MafA
expression in addition to E1 and CRE binding transcrip-
tion factors (29,30). To investigate this speculation, re-
porter gene analysis was performed using MIN6 cells.
Insulin promoter activity was reduced by c-Jun, which was
signiﬁcantly restored by MafA overexpression (Fig. 6).
Importantly, MafA single overexpression had no additional
effect on insulin promoter activity in MIN6 cells. These
ﬁndings suggest that the downregulation of MafA is the
main cause of the suppression of insulin gene transcrip-
tion by c-Jun.
To evaluate whether MafA overexpression prevented
insulin protein loss by c-Jun, we transfected MafA and/or
c-Jun expression plasmids into MIN6 cells. Sixty hours
after the transfection, immunocytochemistry was per-
formed (Fig. 7A). As observed with the adenoviral c-Jun
overexpression in Fig. 4A, c-Jun overexpression by a
plasmid also reduced insulin protein levels (Fig. 7A, top
panels) but was restored by MafA overexpression even in
c-Jun–positive cells (Fig. 7A, bottom panels). To quantify
the effects of MafA on restoration of insulin protein, c-Jun
and MafA were simultaneously overexpressed with the
adenoviral method. As indicated in Fig. 7B, c-Jun–induced
suppression of insulin content was signiﬁcantly prevented
by MafA overexpression. Next, MafA was overexpressed
with Ad-MafA in isolated islets from 17-week-old db/db
mice, since both MafA and insulin expression levels were
suppressed in these islets. Compared with control diabetic
islets infected with Ad-GFP, both insulin 1 and 2 mRNA
levels were signiﬁcantly increased by adenoviral MafA
overexpression in isolated diabetic islets (Fig. 7C). To
clarify that the increased expression of endogenous c-Jun
in diabetic islets is the cause of suppression of insulin and
MafA, c-Jun expression was suppressed by infection of
adenovirus-expressing siRNA of c-Jun (Ad-si-cJun) using
islets isolated from 14-week-old db/db mice in which c-Jun
expression was upregulated. As shown in Fig. 7D, c-Jun
mRNA level was effectively knocked down, and mRNA
levels of insulin 1 and 2 and MafA were signiﬁcantly
increased in diabetic islets. These results clearly indicate
that expression level of MafA and insulin are suppressed
by physiologically increased c-Jun in the islets under
diabetic conditions. Taken together, it is likely that over-
expression of MafA or siRNA of c-Jun restores the c-Jun–
induced suppression of insulin gene transcription and its
protein level.
The domains of c-Jun critical for its suppressive
effects on MafA. The functional domains of c-Jun are
well characterized, and previous reports (30,36) have
demonstrated effective mutants that eliminate the activity
of each domain. We generated expression plasmids and
adenoviruses of various c-Jun mutants, namely c-Jun
transactivation domain (TAD), c-Jun basic region (BS),
and c-Jun leucine zipper domain (LZ), which contain a
deletion or mutation of in the transactivation, basic DNA
binding, and leucine zipper dimerization domain, respec-
tively (Fig. 8A). We ﬁrst conﬁrmed that each plasmid and
adenovirus expressed proteins of the mutant c-Jun ex-
pected size and at adequate amounts by Western blot
analysis (data not shown). As shown by Western blotting
in Fig. 8B, adenoviral expression of c-Jun TAD and c-Jun
BS demonstrated that these mutants did not possess the
activity of c-Jun against the MafA protein, while c-Jun LZ
retained this activity. Furthermore, as shown in Fig. 8C,
insulin transcription activity was also affected by these
mutants in the same way as their alteration of MafA
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arbitrarily set at 100 (n  3). *P < 0.01; **P < 0.001 vs. Ad-GFP infection.
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zipper domain is not required for this activity, we gener-
ated another mutant c-Jun that has two mutations in
amino acids 290 and 297 of the leucine zipper domain.
However, this mutant c-Jun also decreased insulin pro-
moter activity to the same degree as wild-type c-Jun (data
not shown). These ﬁndings indicate that the transactiva-
tion and basic region domains are critical for c-Jun to
suppress MafA and insulin expression.
DISCUSSION
It is well known that insulin gene transcription is down-
regulated under diabetic conditions, although its precise
mechanism is still unclear. One possibility is that ROS
induced by hyperglycemia and/or hyperlipidemia suppress
insulin gene transcription and biosynthesis, as we and
other groups previously suggested. In this study, we
showed that protein levels of c-Jun, whose amount and
activity are upregulated by ROS, are increased in diabetic
islets in vivo, and that, in contrast, MafA protein levels are
markedly decreased (Fig. 1). In addition, immunostaining
of MafA and c-Jun in diabetic islets showed that both MafA
and insulin expression are markedly suppressed in most
c-Jun–positive cells (Fig. 2). These ﬁndings imply that
c-Jun is involved in the suppression of MafA expression.
We further directly demonstrated that c-Jun overexpres-
sion with an expression plasmid or adenovirus markedly
decreases MafA and insulin expression in isolated islets as
well as MIN6 cells (Figs. 3 and 4) and that overexpression
of MafA markedly, but not completely, recovered insulin
promoter activity suppressed by c-Jun (Fig. 6). These
results indicate that increased expression of c-Jun sup-
presses insulin gene expression via the decrease of MafA
expression, besides its direct suppressive effect on insulin
gene promoter activity through the cyclic AMP response
element as reported previously. Since MafA appears to not
only regulate insulin expression but also to be involved in
insulin secretion (37,38), it is likely that the suppression of
MafA protein levels by c-Jun leads to insulin secretory
defects that are often observed under diabetic conditions.
c-Jun is well known to induce apoptosis in a variety of
cells. On the other hand, disruption of the c-jun gene in
mice showed that c-Jun is required for cell proliferation
and differentiation (39,40). These opposite effects of c-Jun
on both the promotion of and protection from apoptosis
might depend on the type, severity, and length of stimuli,
as well as the effects of additional factors and/or cell types.
First, to examine whether the suppressive effect of c-Jun
on MafA and insulin expression is simply due to the
induction of apoptosis, we isolated DNA from MIN6 cells
infected with Ad-c-Jun for 1, 2, or 3 days and analyzed
DNA fragmentation by electrophoresis. However, DNA
ladders were not detected in these experiments (supple-
mental Fig. 3). Furthermore, since overexpression of MafA
prevented the suppressive effects of c-Jun on insulin
promoter activity (Fig. 6) and protein levels (Fig. 7), it is
unlikely that c-Jun induced apoptosis, at least in our
model. Interestingly, some of the increased Ki67-positive
cells also expressed c-Jun in the islets of db/db mice
(supplemental Fig. 4), which indicates that c-Jun–positive
cells are able to proliferate. These results suggest that
c-Jun–mediated -cell dysfunction is not simply due to the
induction of apoptosis, although the physiological reason
as to why c-Jun is induced in pancreatic islets under
diabetic conditions remains unknown.
As reported previously, MafA is a phosphorylated pro-
tein, and phosphorylation is critical for its activity (41–43).
In this study, p38 and JNK, both of which are activated by
ROS, were evaluated by these overexpression experi-
ments; however, we observed no effects on insulin and
MafA expression. This is consistent with the previous
ﬁndings that MafA is not phosphorylated by p38 in vitro
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c-Jun, we predicted that the JNK pathway might also be
involved in the alteration of MafA activity. However, the
effects of c-Jun on insulin promoter activity and MafA
protein levels were not inhibited by a dominant negative
form of JNK (data not shown). Therefore, we assume that
the induction of c-Jun expression, per se, is more impor-
tant for the suppression of MafA expression. However, as
shown in Fig. 8, the TAD of c-Jun, which includes its
phosphorylation site by JNK, is apparently important for
its suppression of MafA. These ﬁndings suggest that a
relatively small amount of JNK is enough to activate c-Jun
and suppress MafA.
In this study, we showed that the protein levels of MafA
and insulin are simultaneously reduced in the islets of
diabetic mice. These results are consistent with the previ-
ous ﬁndings that RIPE3b1-binding activity is reduced in
diabetic islets (18) and that chronic high glucose de-
creases insulin promoter activity through the reduction of
RIPE3b1 activity in HIT-T15 cells (10,19). However, this is
the ﬁrst report to show the increase of c-Jun expression
and the decrease of both MafA and insulin expression
under diabetic conditions in vivo and to directly demon-
strate that the increased c-Jun expression suppresses both
MafA and insulin expression.
In conclusion, the ﬁndings reported in this study suggest
that the augmented expression of c-Jun in diabetic islets
decreases MafA activity followed by reduced insulin bio-
synthesis and thereby explains, at least in part, the molec-
ular mechanism for -cell glucose toxicity that is often
observed in type 2 diabetic patients.
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